Get startedLog in
    Picture of SciClone Pharmaceuticals (Holdings) logo

    6600 — SciClone Pharmaceuticals (Holdings) News Story

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareSpeculativeMid Cap
    All News

    Brief: Sciclone Pharmaceuticals Gets NMPA Approval Of IND Of Danyelza® (Naxitamab) And GM-Csf

    Picture of SciClone Pharmaceuticals (Holdings) logoSciClone Pharmaceuticals (Holdings)
    28/06/2022 02:27
    June 28 (Reuters) - SciClone Pharmaceuticals (Holdings) Ltd
 6600.HK :
    * NMPA APPROVAL OF IND OF DANYELZA® (NAXITAMAB) AND GM-CSF
IN
COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE

Further company coverage:  6600.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on SciClone Pharmaceuticals (Holdings)

    See all news